December 2007 Oncology News International

AI-assisted training dramatically reduced HER2-null overscoring and improved sensitivity in HER2-low and HER2-ultralow breast cancer cases.

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

The phase 3 IMforte trial evaluating lurbinectedin plus atezolizumab is the first to show PFS and OS improvement with first-line maintenance for ES-SCLC.

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

There was a 7% lower incidence of obesity-related cancer with GLP-1 receptor agonist use.

Survival and safety data from the phase 3 CheckMate 9DW trial showed that nivolumab plus ipilimumab was superior to lenvatinib or sorafenib in advanced HCC.